Xponance Inc. Buys 1,052 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Xponance Inc. grew its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 13.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,905 shares of the company’s stock after purchasing an additional 1,052 shares during the quarter. Xponance Inc.’s holdings in Vaxcyte were worth $729,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Whipplewood Advisors LLC bought a new position in Vaxcyte during the 4th quarter valued at $28,000. Smartleaf Asset Management LLC lifted its position in shares of Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after purchasing an additional 260 shares in the last quarter. Blue Trust Inc. boosted its holdings in Vaxcyte by 100.0% during the fourth quarter. Blue Trust Inc. now owns 742 shares of the company’s stock worth $61,000 after purchasing an additional 371 shares during the last quarter. Assetmark Inc. grew its position in Vaxcyte by 77,500.0% in the 4th quarter. Assetmark Inc. now owns 776 shares of the company’s stock worth $64,000 after purchasing an additional 775 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. purchased a new stake in Vaxcyte in the 3rd quarter valued at about $92,000. Institutional investors own 96.78% of the company’s stock.

Insider Activity at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $86.51, for a total transaction of $692,080.00. Following the sale, the chief financial officer now owns 109,491 shares of the company’s stock, valued at $9,472,066.41. The trade was a 6.81 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Teri Loxam sold 6,250 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the transaction, the director now directly owns 7,175 shares of the company’s stock, valued at $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,250 shares of company stock worth $3,840,018. 3.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on PCVX. The Goldman Sachs Group began coverage on Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 target price on the stock. Guggenheim restated a “buy” rating and issued a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday, March 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, February 26th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $147.50.

Vaxcyte Price Performance

Shares of PCVX opened at $73.82 on Tuesday. Vaxcyte, Inc. has a 1 year low of $58.10 and a 1 year high of $121.06. The stock’s fifty day moving average price is $81.26 and its two-hundred day moving average price is $93.61. The firm has a market cap of $9.51 billion, a PE ratio of -16.05 and a beta of 1.02.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14. Sell-side analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.